Peter Libby: Mast Cells in Cardiovascular Disease
Peter Libby, Mallinckrodt Professor of Medicine and Cardiovascular Specialist at Harvard Medical School and Mass General Brigham Hospital, shared a post on LinkedIn:
“Every leukocyte class shall have its day in atherosclerosis. With an international team, we summarize the current evidence supporting mechanisms by which mast cells can participate in this disease. Inflammation has many faces, and reaginic antibody (IgEs) can link adaptive to innate immunity unleashing a multitude of mast cell mediators that can modulate arterial and microvascular biology.”
Title: Mast cells in cardiovascular disease: Fibrosis, angiogenesis and atherogenesis
Authors: Gabriel Bueno, Ilze Bot, Anish A. Kanhai, Roberta Stilhano, Peter Libby, Guido R.Y. De Meyer, Leonardo Martin
Stay informed with Hemostasis Today.
-
Jul 23, 2026, 19:25William Archibald: Key Takeaways on VTE Cost-Effectiveness and Cancer Associated Thrombosis from ISTH 2026
-
Jul 23, 2026, 19:17Diego López Santos: Donation after Donation, I Just Reached 100
-
Jul 23, 2026, 19:11Jecko Thachil: Chlorosis May Have Represented Iron Deficiency in the 19th Century
-
Jul 23, 2026, 15:58Mel Snyder: Beyond Sickle Cell Disease to the Future of Pediatric Genetics
-
Jul 23, 2026, 15:43Lorna Knight: The Next Frontier in Sickle Cell Disease Is Access
-
Jul 23, 2026, 15:29Ben Kleinstiver: Overcoming a Major Barrier to Scalable Gene Editing
-
Jul 23, 2026, 15:28Modernizing DIC Diagnosis in Cirrhosis: Building an International Registry for Precision Hemostasi
-
Jul 23, 2026, 14:32Saneha Anjum Shaikh: Why Antibody Screening Must Be Standard Practice in Modern Blood Banking
-
Jul 23, 2026, 14:00Ron Vezina: Canadian Blood Services Issues Urgent Donation Appeal